A Clinical Study to Assess Preliminary Efficacy, Safety and Tolerability of HH-120 Nasal Spray in COVID-19 Patients
Launched by BEIJING DITAN HOSPITAL · Dec 20, 2022
Trial Information
Current as of February 05, 2025
Completed
Keywords
ClinConnect Summary
During this study, participants will receive HH-120 nasal spray treatment for 6 consecutive days, the efficacy and safety of HH-120 will be assessed throughout the study period based on viral clearance, clinical recovery, illness severity and adverse events.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 to 65 years old.
- • Participants with mild COVID-19 with symptom onset≤5 days or asymptomatic COVID-19.
- • Participants being able and willing to provide informed consent prior to any study-specific procedure.
- Exclusion Criteria:
- • Participants with moderate or severe COVID-19.
- • Participants within the pregnancy or breastfeeding period or plan to be pregnant during the study period.
- • Participants requiring oxygen treatment (such as non-invasive ventilation, invasive mechanical ventilation, ECMO, etc.).
- • Participants with nasal disease that is inconvenient or intolerant of nasal spray administration, or cannot use the nasal spray treatment.
- • Participants with comorbid Malignancy or with a history of malignancy.
- • Participants with active or uncontrolled systemic autoimmune disease.
- • Insufficient function of key organs.
- • Other reasons considered by the investigator to be unsuitable for the trial.
About Beijing Ditan Hospital
Beijing Ditan Hospital is a leading healthcare institution in China, renowned for its expertise in neurology and neurosurgery. As a prominent clinical trial sponsor, the hospital is dedicated to advancing medical research and improving patient outcomes through innovative studies and rigorous scientific methodologies. With a commitment to ethical standards and patient safety, Beijing Ditan Hospital collaborates with multidisciplinary teams to explore new therapies and interventions, contributing to the global body of knowledge in the medical field. Its state-of-the-art facilities and experienced researchers position the hospital at the forefront of clinical research, fostering breakthroughs that enhance healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Beijing, Beijing, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials